(VIANEWS) - La (LZB), Bruker Corporation (BRKR), United Therapeutics Corporation (UTHR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. La (LZB)
19.2% sales growth and 17.29% return on equity
La-Z-Boy Incorporated produces, markets, imports and exports, distributes and sells upholstery, casegoods and accessories furniture products throughout the United States and Canada.
La's sales growth this year is expected to be 31.4% and 1.2% for next year.
Year-on-year quarterly revenue growth grew by 25.4%, now sitting on 2.09B for the twelve trailing months.
Volume
Today's last reported volume for La is 250192 which is 51.56% below its average volume of 516555.
La's sales growth is a negative 0% for the ongoing quarter and 19.2% for the next. The company's growth estimates for the present quarter and the next is 20.3% and 58.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.29%.
Volatility
La's last day, last week, and last month's current intraday variation average was 0.91%, 1.28%, and 1.57%, respectively.
La's highest amplitude of average volatility was 1.96% (day), 2.62% (last week), and 3.42% (last month), respectively.
La's Stock Yearly Top and Bottom Value
La's stock is valued at $27.64 at 16:22 EST, way below its 52-week high of $46.74 and above its 52-week low of $26.88.
La's Moving Average
La's value is way below its 50-day moving average of $31.51 and way below its 200-day moving average of $34.20.2. Bruker Corporation (BRKR)
12.8% sales growth and 26.88% return on equity
Bruker Corporation designs, produces, and distributes analytical and diagnostic instruments in the United States and Europe.
Bruker Corporation's sales growth this year is anticipated to be 20.5% and 5.7% for next year.
Year-on-year quarterly revenue growth grew by 19.1%, now sitting on 2.36B for the twelve trailing months.
Volume
Today's last reported volume for Bruker Corporation is 631548 which is 23.38% below its average volume of 824280.
Bruker Corporation's sales growth for the next quarter is 12.8%. The company's growth estimates for the ongoing quarter and the next is a negative 0% and 11.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.88%.
Volatility
Bruker Corporation's last day, last week, and last month's current intraday variation average was 5.24%, 2.26%, and 2.73%, respectively.
Bruker Corporation's highest amplitude of average volatility was 5.81% (day), 3.61% (last week), and 4.40% (last month), respectively.
Bruker Corporation's Stock Yearly Top and Bottom Value
Bruker Corporation's stock is valued at $64.30 at 16:22 EST, way under its 52-week high of $92.35 and higher than its 52-week low of $61.42.
Bruker Corporation's Moving Average
Bruker Corporation's value is under its 50-day moving average of $67.09 and way below its 200-day moving average of $77.15.3. United Therapeutics Corporation (UTHR)
11.2% sales growth and 12.94% return on equity
United Therapeutics Corporation is a biotech company that develops and markets products for patients living with life-threatening and chronic diseases.
United Therapeutics Corporation's sales growth this year is anticipated to be 14.3% and 10.7% for next year.
Year-on-year quarterly revenue growth grew by 7.9%, now sitting on 1.69B for the twelve trailing months.
Volume
Today's last reported volume for United Therapeutics Corporation is 354566 which is 24.1% below its average volume of 467163.
United Therapeutics Corporation's sales growth for the next quarter is 11.2%. The company's growth estimates for the present quarter and the next is 63.9% and 452.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.94%.
Volatility
United Therapeutics Corporation's last day, last week, and last month's current intraday variation average was 0.37%, 1.48%, and 1.42%, respectively.
United Therapeutics Corporation's highest amplitude of average volatility was 2.55% (day), 3.06% (last week), and 3.48% (last month), respectively.
United Therapeutics Corporation's Stock Yearly Top and Bottom Value
United Therapeutics Corporation's stock is valued at $184.71 at 16:22 EST, way under its 52-week high of $218.38 and way above its 52-week low of $158.38.
United Therapeutics Corporation's Moving Average
United Therapeutics Corporation's worth is below its 50-day moving average of $186.64 and below its 200-day moving average of $193.88.4. Gladstone Investment Corporation (GAIN)
8.8% sales growth and 26.23% return on equity
Gladstone Investment Corporation is a specialist in buyouts of mature and lower-middle market debt. It also offers senior and junior debt securities, such as senior terms loans, lines and notes, and senior subordinated securities.
Gladstone Investment Corporation's sales growth this year is anticipated to be 23.1% and a negative 4.1% for next year.
Year-on-year quarterly revenue growth declined by 3.6%, now sitting on 70.01M for the twelve trailing months.
Volume
Today's last reported volume for Gladstone Investment Corporation is 64588 which is 48.74% below its average volume of 126025.
Gladstone Investment Corporation's sales growth for the next quarter is 8.8%. The company's growth estimates for the present quarter and the next is 155.6% and 414.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.23%.
Gladstone Investment Corporation's Stock Yearly Top and Bottom Value
Gladstone Investment Corporation's stock is valued at $16.32 at 16:22 EST, under its 52-week high of $17.15 and way higher than its 52-week low of $12.46.